LigaChem Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
LigaChem Biosciences has a total shareholder equity of ₩625.0B and total debt of ₩11.8B, which brings its debt-to-equity ratio to 1.9%. Its total assets and total liabilities are ₩739.3B and ₩114.3B respectively.
Key information
1.9%
Debt to equity ratio
₩11.85b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩557.28b |
| Equity | ₩624.98b |
| Total liabilities | ₩114.35b |
| Total assets | ₩739.33b |
Recent financial health updates
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23Recent updates
LigaChem Biosciences (KOSDAQ:141080) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 09Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07
Financial Position Analysis
Short Term Liabilities: A141080's short term assets (₩583.0B) exceed its short term liabilities (₩107.4B).
Long Term Liabilities: A141080's short term assets (₩583.0B) exceed its long term liabilities (₩6.9B).
Debt to Equity History and Analysis
Debt Level: A141080 has more cash than its total debt.
Reducing Debt: A141080's debt to equity ratio has increased from 0% to 1.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A141080 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A141080 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 1.3% per year.